Alessio Cortellini, Consultant Medical Oncologist and Assistant Professor at Campus Bio-Medico University of Rome, shared a post on LinkedIn:
“Really happy to share that our systematic review and meta-analysis on PD-(L)1 rechallenge strategies in advanced NSCLC is finally out in Cancer Treatment Reviews.
Together with an outstanding global group of experts, we reviewed the available evidence in a clinical space that remains highly underserved and still full of unanswered questions: how to approach patients with NSCLC progressing after prior immunotherapy.
Overall, the magnitude of benefit observed with PD-(L)1 rechallenge strategies appears modest and heterogeneous. However, an interesting signal emerged in patients with features of acquired resistance to prior immunotherapy, suggesting that not all resistance phenotypes are biologically equivalent and that some patients may still retain residual immune sensitivity.
While these findings remain exploratory and should be interpreted cautiously, we hope this work can help bring some clarity to a very difficult therapeutic setting and support future drug development efforts in this space, where many of us still believe there is room to improve outcomes for patients.
A big thank you to Daniele Marinelli for leading this huge effort, and to all the co-authors and collaborators involved in this work.
Very proud of this international collaboration!”
Title: PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes
Authors: Daniele Marinelli, Fabrizio Citarella, Andrea Torchia, Sagal Pannu, Ayesha Aijaz, Luisana Sisca, Marco Russano, Yu Fujiwara, Kazuki Takada, Amin H. Nassar, Giuseppe Luigi Banna, Biagio Ricciuti, Leonardo Brunetti, Valentina Santo, Antonio Passaro, Stephanie P.L. Saw, Molly S.C. Li, Alfredo Addeo, Roberto Ferrara, Massimo Di Maio, Alessio Cortellini.
Read the article: here.
Other articles about NSCLC on OncoDaily.